Lessons From Hydroxychloroquine: Improving FDA’s Authorization and Approval Process
On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use ...
From Our Partners
On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use ...
The National Institutes of Health has issued an urgent funding opportunity announcement to invite applications to repurpose existing therapeutic agents ...
Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the ...
An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well ...
Thailand’s National Vaccine Institute (NVI) at Chulalongkorn University today began testing a trial vaccine against the novel coronavirus on non-human ...
Extracorporeal treatment reprograms white blood cells to fight inflammation. As part of a randomized controlled trial, a team from Lawson ...
The first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to ...
A large observational study published this week in The Lancet suggests that treatment with the antimalarial drug chloroquine or its ...
In mice, rats, and nonhuman primates, a newly developed SARS-CoV-2 virus vaccine candidate induced antibodies that neutralized several different SARS-CoV-2 ...
The first U.S. patients have been dosed in a clinical trial testing whether four experimental mRNA vaccine candidates can prevent ...
Since the World Health Organization declared COVID-19 a Public Health Concern of Global Interest on January 30, more than one ...
"The results of this vaccine trial are also important and promising with regard to the development of a vaccine against ...
A team of Johns Hopkins experts has created a clinical guidebook to help hospitals and medical centers rapidly scale up ...
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical ...
Alexion Pharmaceuticals Inc. announced today it would start a late-stage study of its rare blood-disorder drug, Ultomiris, in COVID-19 patients ...
Infectious disease scientists report early development of a potential universal vaccine for Ebola viruses that preclinical tests show might neutralize ...
With no drugs or vaccines yet approved for COVID-19 and the number of U.S. cases increasing by the thousands every ...
The FDA is facilitating access to convalescent plasma, antibody-rich blood products that are taken from blood donated by people who ...
U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately Regeneron is leading U.S. trials, Sanofi will lead upcoming ex-U.S. trials Regeneron Pharmaceuticals, ...
A randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir in hospitalized adults diagnosed ...
